ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1137

MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy

Kristin Wipfler1, Joshua Baker2 and Kaleb Michaud3, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Keywords: Anti-TNF Drugs, genetics, Patient reported outcomes, prognostic factors, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Genetics, Genomics and Proteomics Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: MHC class I polypeptide-related sequence A (MICA) is a protein involved in the activation of NK and T cells. Variants within the MICA gene have been linked to susceptibility to numerous rheumatic diseases, including RA, PsA, AS, JIA, and SLE, and one variant (rs1051792) has been associated with therapeutic response to TNF inhibitors (TNFi) in patients with RA.1 The objective of this study was to examine the relationships between MICA variants and TNFi response in individuals with RA in a real-world setting.

Methods: Data were provided by adults with RA who provided biosamples and initiated a TNFi during observation in FORWARD, The National Databank for Rheumatic Diseases. These individuals had a baseline observation (prior to medication start) and a follow up observation (after medication start) approximately six months later. Genotyping was performed with the Illumina Infinium Global Screening Array platform, and non-silent common (minor allele frequency > 0.05) MICA variants were included in this analysis (rs1063632, rs1051794, rs1131896, and rs9266825). Change in disease activity following TNFi initiation was measured by minimal clinically important difference (MCID) in the patient activity scale II (PAS-II). The MCID cutoff from baseline to follow up was 0.63 if baseline PAS-II >3.7 and was 0.53 if baseline PAS-II≤3.7. Logistic regression models for achieving MCID were generated for each of the four variants by number of minor alleles present (0, 1, or 2; 0 referent) and were adjusted for baseline PAS-II, age, sex, white race, smoking history, calendar year, RA duration, BMI, glucocorticoid use, and Rheumatic Disease Comorbidity Index (RDCI).

Results: A total of 197 participants met inclusion criteria, 70 of whom (36%) reached the MCID for improved PAS-II following initiation of a TNFi. Baseline characteristics are presented in Table 1 and allele distributions for each variant are presented in Table 2. Of the four variants examined, rs1131896 was significantly associated with improved disease activity following initiation of a TNFi (Figure 1). Individuals who were homozygous for the minor allele at rs1131896 had six times the odds of achieving the MCID for improved PAS-II (OR [95% CI] 6.1 [1.5, 24.1]; p=0.01) compared to those who were homozygous for the major allele. Heterozygous individuals did not have a significant association between their genotype and improved PAS-II scores.

Conclusion: Our results indicate that individuals with RA who are homozygous for the minor allele at MICA rs1131896 are significantly more likely to experience clinically important improvements in disease activity following use of a TNFi. While other MICA variants have been associated with rheumatic diseases and drug response, this is the first study to link rs1131896 with TNF outcomes. This variant may serve as a useful predictor of TNFi response as part of ongoing efforts to improve precision medicine for RA. Future work to confirm this result in additional cohorts and investigate a functional explanation is needed.

1. Iwaszko, M. et al. Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis. Pharmacogenomics J 20, 760-769 (2020).

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: K. Wipfler, None; J. Baker, Bristol-Myers Squibb(BMS), RediTrex, Pfizer; K. Michaud, None.

To cite this abstract in AMA style:

Wipfler K, Baker J, Michaud K. MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/mhc-class-i-polypeptide-related-sequence-a-variant-predicts-real-world-response-to-anti-tnf-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mhc-class-i-polypeptide-related-sequence-a-variant-predicts-real-world-response-to-anti-tnf-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology